Page 99 - OR-1-1

6. Nakachi K, Ikeda M, Konishi M, et al. Adjuvant S-1 compared doi: 10.1016/j.stem.2019.10.010
with observation in resected biliary tract cancer (JCOG1202, 13. Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine
ASCOT): A multicentre, open-label, randomised, controlled, versus gemcitabine for biliary tract cancer. N Engl J Med.
phase 3 trial. Lancet. 2023;401(10372):195-203. 2010;362(14):1273-1281.
doi: 10.1016/s0140-6736(22)02038-4 doi: 10.1056/NEJMoa0908721
7. O’Rourke CJ, Salati M, Rae C, et al. Molecular portraits of 14. Primrose JN, Fox RP, Palmer DH, et al. Capecitabine
patients with intrahepatic cholangiocarcinoma who diverge compared with observation in resected biliary tract cancer
as rapid progressors or long survivors on chemotherapy. Gut. (BILCAP): A randomised, controlled, multicentre, phase 3
2024;73(3):496-508. study. Lancet Oncol. 2019;20(5):663-673.
doi: 10.1136/gutjnl-2023-330748 doi: 10.1016/s1470-2045(18)30915-x
8. Xu H, Jiao D, Liu A, Wu K. Tumor organoids: Applications 15. Wang Y, Li J, Xia Y, et al. Prognostic nomogram for
in cancer modeling and potentials in precision medicine. intrahepatic cholangiocarcinoma after partial hepatectomy.
J Hematol Oncol. 2022;15(1):58. J Clin Oncol. 2013;31(9):1188-1195.
doi: 10.1186/s13045-022-01278-4 doi: 10.1200/jco.2012.41.5984
9. Tang XY, Wu S, Wang D, et al. Human organoids in basic 16. Ma X, Wang Q, Li G, Li H, Xu S, Pang D. Cancer organoids:
research and clinical applications. Signal Transduct Target A platform in basic and translational research. Genes Dis.
Ther. 2022;7(1):168. 2024;11(2):614-632.
doi: 10.1038/s41392-022-01024-9 doi: 10.1016/j.gendis.2023.02.052

10. Spolverato G, Yakoob MY, Kim Y, et al. The impact of 17. Seppälä TT, Zimmerman JW, Suri R, et al. Precision
surgical margin status on long-term outcome after resection medicine in pancreatic cancer: Patient-derived organoid
for intrahepatic cholangiocarcinoma. Ann Surg Oncol. pharmacotyping is a predictive biomarker of clinical
2015;22(12):4020-4028. treatment response. Clin Cancer Res. 2022;28(15):3296-3307.
doi: 10.1245/s10434-015-4472-9 doi: 10.1158/1078-0432.Ccr-21-4165
11. De Witte CJ, Espejo Valle-Inclan J, Hami N, et al. Patient- 18. Liang C, Shan D, Wei Z. PDO-based drug screening
derived ovarian cancer organoids mimic clinical response in advanced pancreatic cancer. Gastroenterology.
and exhibit heterogeneous inter-and intrapatient drug 2024;168:627-628.
responses. Cell Rep. 2020;31(11):107762. doi: 10.1053/j.gastro.2024.10.045
doi: 10.1016/j.celrep.2020.107762 19. Boilève A, Cartry J, Goudarzi N, et al. Organoids for
12. Yao Y, Xu X, Yang L, et al. Patient-derived organoids predict functional precision medicine in advanced pancreatic
chemoradiation responses of locally advanced rectal cancer. cancer. Gastroenterology. 2024;167(5):961-976.e13.
Cell Stem Cell. 2020;26(1):17-26.e6. doi: 10.1053/j.gastro.2024.05.032

Volume 1 Issue 1 (2025) 12 doi: 10.36922/or.8571